BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations
BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations · Investor's Business Daily

In This Article:

BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.